Skip to main content
Smart Investors Daily
EM

NASDAQ · EMBC

Embecta Corp.

Healthcare · Drug Manufacturers - Specialty & Generic

$6.19

Up+$0.10 (+1.64%)

Updated Nov 20, 2026, 2:01 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
699.2M
P/E ratio
7.38
Dividend yield
9.69%
52-week range
$2.77 – $14.78
Volume
836.07K
Avg. volume
483.6K

Price performance · EMBC

EMBC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

EMBC closed at $6.19 after 21 trading sessions, down 9.77% for the selected period.

Last close
$6.19
Period change
-9.77%
Period low
$6.08
Period high
$6.86
Daily close
View OHLC price history
EMBC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$6.07$6.22$5.79$6.19836.07K
Nov 18, 2026$6.07$6.294$5.98$6.09716.06K
Nov 17, 2026$6.12$6.26$6.02$6.15933.86K
Nov 16, 2026$6.42$6.5659$6.165$6.25947.83K
Nov 13, 2026$6.46$6.495$6.16$6.46566.84K
Nov 12, 2026$6.51$6.585$6.39$6.43973.99K
Nov 11, 2026$6.41$6.595$6.3503$6.53721.02K
Nov 10, 2026$6.32$6.465$6.195$6.43804.62K
Nov 9, 2026$6.24$6.435$6.14$6.41604.35K
Nov 6, 2026$6.11$6.39$5.78$6.19623.13K
Nov 5, 2026$6.58$6.6599$6.23$6.33780.11K
Nov 4, 2026$6.25$6.79$6.20$6.521.15M
Nov 3, 2026$6.17$6.285$6.05$6.08570.29K
Nov 2, 2026$6.28$6.36$6.13$6.19658.22K
Oct 30, 2026$6.55$6.58$6.195$6.25831.1K
Oct 29, 2026$6.52$6.695$6.45$6.561.11M
Oct 28, 2026$6.54$6.60$6.3706$6.46985K
Oct 27, 2026$6.80$6.895$6.49$6.551.28M
Oct 26, 2026$6.70$6.83$6.6499$6.80679.49K
Oct 23, 2026$6.77$6.88$6.69$6.71717.02K
Oct 22, 2026$6.64$6.90$6.625$6.86922.04K

Latest EMBC news

The latest Smart Investors Daily articles mentioning EMBC.

EMBC research

Overview

Company profile and research snapshot.

Company profile

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$22.50
Implied upside
—
Analysts
9
EMBC recent ratings
DateFirmRatingTarget
May 18, 2026B of A SecuritiesUnderperform—
May 6, 2026MizuhoNeutral—
May 6, 2026BTIGNeutral—
Apr 13, 2026MizuhoNeutral—
Feb 6, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 7, 2026

Why Embecta Bears Were Right Before A 54% Drop

If you had paused on Embecta in late 2025, wondering whether steady diabetes-device cash flows and analyst price targets justified a position, the past year has delivered a harsh answer. Investors who held Embecta over the past year are down 53.6%, including dividends. With lawsuits now alleging misleading guidance and weak pen needle demand, the real question is which assumptions about earnings visibility and product resilience were already sitting in plain sight back on 6 November...

Yahoo · Oct 20, 2026

What Embecta Bears Saw Before A 55% Drop

If you had backed Embecta on 19 October 2025 and simply held on, the experience would have been brutal. Holding Embecta over the past year would have meant a 54.5% loss, including dividends. At the start, bullish and bearish analysts were arguing over modest revenue shrinkage, margin expansion into the mid teens, and a future P/E between 7.4x and 4.7x. So what did that original investment case miss about pen needle reliance, GLP-1 partnerships and margin durability? The move put Embecta in...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.